Evidence map›Paper›PMID 33167503›Full record

ArticleJournal of clinical medicine2020

Trends in the Prescription of Non-Vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation: Results of the Polish Atrial Fibrillation (POL-AF) Registry.

Iwona Gorczyca, Olga Jelonek, Beata Uziębło-Życzkowska, Magdalena Chrapek, Małgorzata Maciorowska, Maciej Wójcik, Robert Błaszczyk, Agnieszka Kapłon-Cieślicka, Monika Gawałko, Monika Budnik and 12 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 8 institutions in 1 country.

Iwona GorczycaCollegium Medicum, The Jan Kochanowski University, 25-369 Kielce, Poland.ORCID 0000-0002-7619-8426
Olga JelonekCollegium Medicum, The Jan Kochanowski University, 25-369 Kielce, Poland.ORCID 0000-0002-2179-9945
Beata Uziębło-ŻyczkowskaDepartment of Cardiology and Internal Diseases, Military Institute of Medicine, 04-141 Warsaw, Poland.
Magdalena ChrapekFaculty of Natural Sciences, The Jan Kochanowski University, 25-369 Kielce, Poland.
Małgorzata MaciorowskaDepartment of Cardiology and Internal Diseases, Military Institute of Medicine, 04-141 Warsaw, Poland.ORCID 0000-0001-5242-7522
Maciej WójcikDepartment of Cardiology, Medical University of Lublin, 20-059 Lublin, Poland.
Robert BłaszczykDepartment of Cardiology, Medical University of Lublin, 20-059 Lublin, Poland.ORCID 0000-0003-1853-5006
Agnieszka Kapłon-Cieślicka1st Chair and Department of Cardiology, Medical University of Warsaw, 02-097 Warsaw, Poland.
Monika Gawałko1st Chair and Department of Cardiology, Medical University of Warsaw, 02-097 Warsaw, Poland.ORCID 0000-0003-4619-9062
Monika Budnik1st Chair and Department of Cardiology, Medical University of Warsaw, 02-097 Warsaw, Poland.
Tomasz TokarekDepartment of Cardiology and Cardiovascular Interventions, University Hospital, 30-688 Krakow, Poland.
Renata Rajtar-SalwaDepartment of Cardiology and Cardiovascular Interventions, University Hospital, 30-688 Krakow, Poland.
Jacek BilDepartment of Invasive Cardiology, Centre of Postgraduate Medical Education, Central Clinical Hospital of the Ministry of Interior and Administration, 02-507 Warsaw, Poland.ORCID 0000-0002-8724-5611
Michał WojewódzkiDepartment of Invasive Cardiology, Centre of Postgraduate Medical Education, Central Clinical Hospital of the Ministry of Interior and Administration, 02-507 Warsaw, Poland.ORCID 0000-0002-1082-3831
Anna SzpotowiczDepartment of Cardiology, Regional Hospital, 27-400 Ostrowiec Swiętokrzyski, Poland.
Janusz BednarskiDepartment of Cardiology, St John Paul II Western Hospital, 05-825 Grodzisk Mazowiecki, Poland.
Elwira Bakuła-OstalskaDepartment of Cardiology, St John Paul II Western Hospital, 05-825 Grodzisk Mazowiecki, Poland.
Anna Tomaszuk-KazberukDepartment of Cardiology, Medical University, 15-276 Bialystok, Poland.
Anna SzyszkowskaDepartment of Cardiology, Medical University, 15-276 Bialystok, Poland.
Marcin Wełnicki3rd Department of Internal Diseases and Cardiology, Warsaw Medical University, 02-091 Warsaw, Poland.ORCID 0000-0002-7454-521X
Artur Mamcarz3rd Department of Internal Diseases and Cardiology, Warsaw Medical University, 02-091 Warsaw, Poland.ORCID 0000-0002-9569-1486
Beata Wożakowska-KapłonCollegium Medicum, The Jan Kochanowski University, 25-369 Kielce, Poland.
Medical University of Warsaw · PLJan Kochanowski University · PLJohn Paul II Hospital · PLMedical University of Białystok · PLMedical University of Lublin · PLMinistry of Interior and Administration · PLWojskowy Instytut Medycyny Lotniczej · PLCelsa (Poland) · PL

Funding

Jan Kochanowski University 024/RID/2018/1The Jan Kochanowski University 024/RID/2018/19
6 · The paper itself

Abstract

backgroundCurrent guidelines do not suggest in which groups of patients with atrial fibrillation (AF) individual non-vitamin K antagonist oral anticoagulants (NOACs) should be used for the prevention of thromboembolic complications. The aim of this study was to evaluate the frequency of use of apixaban, dabigatran, and rivaroxaban, and attempt to identify factors predisposing their administration.

methodsThe Polish Atrial Fibrillation (POL-AF) registry is a prospective, non-interventional study, including consecutive patients with AF hospitalized in ten Polish cardiology centers during the period ranging from January to December 2019. In this study, all patients were treated with NOACs.

resultsAmong the 2971 patients included in the analysis, 40.4% were treated with rivaroxaban, 32% with apixaban, and 27.6% with dabigatran. The mean age of the total population was 72 ± 11.5 years and 43% were female. A reduced dose of NOAC was used in 35% of patients treated with apixaban, 39.7% of patients treated with dabigatran, and 34.4% of patients treated with rivaroxaban. Independent predictors of the use of apixaban were previous bleeding (OR 2.37, CI 1.67–3.38), GFR < 60 mL/min (OR 1.38, CI 1.25–1.64), heart failure (OR 1.38, CI 1.14–1.67) and age (per 5 years) (OR 1.14, CI 1.09–1.19). GFR < 60 mL/min (OR 0.79, CI 0.66–0.95), female (OR 0.8, CI 0.67–0.96) and age (per 5 years) (OR 0.95, CI 0.91–0.99) diminished the chance of using dabigatran. Previous bleeding (OR 0.43, CI 0.28–0.64), vascular disease (OR 0.84, CI 0.70–0.99), and age (per 5 years) (OR 0.94, CI 0.90–0.97) diminished the chance of choosing rivaroxaban.

conclusionsIn hospitalized patients with AF, the most frequently chosen NOAC was rivaroxaban. Apixaban was chosen more often in patients after bleeding, and in those who were advanced in years, with heart failure and impaired renal function. Impaired renal function and female gender were factors that diminished the chance of using dabigatran. Previous bleeding and vascular disease was the factor that diminished the chance of using rivaroxaban. Dabigatran and rivaroxaban have been used less frequently in elderly patients.

Indexed as

atrial fibrillationnon-vitamin K antagonist oral anticoagulantsoral anticoagulantsvitamin K antagonists

Identifiers

PMID33167503
PMCPMC7694480
OpenAlexW3097288437

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.